Sutro Biopharma

Sutro Biopharma

A biopharmaceutiical company discovering, developing and manufacturing therapeutics for the treatment of canccer

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

July 2018
Sutro Biopharma raises a $85,400,000 series E round from Lilly Ventures, Samsara BioCapital, Alta, Skyline Ventures, Amgen Ventures, SV Health Investors, Celgene and Surveyor Capital.
December 11, 2013
Sutro Biopharma raises a $26,000,000 series D round from Amgen, Skyline Ventures, Alta Partners and Celgene.
November 17, 2010
Sutro Biopharma raises a $36,500,000 series C round from Amgen, Skyline Ventures, Alta Partners and Lilly Ventures.
December 10, 2007
Sutro Biopharma raises a $21,000,000 series B round from Alta Partners.
January 1, 2006
Sutro Biopharma raises a $1,000,000 series A round.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Sutro Biopharma Inc funding round, July 2018
85,400,000
July 2018
6 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Alison Polite

Employee

Avi Hermosa Petel

Employee

Gabriel Jagoe-Seidl

Employee

Jay Shukert

Employee

Jennifer Batara

Employee

Kenneth Larsen

Employee

Lillian Tong

Employee

Marcie Arjona

Employee

Marianna Pristupa

Employee

Patricia Sinatra

Investor

Peter Priel

Employee

Philip Tagari

Investor

Sutanto Widjaja

Founder

Tessi Kanavarioti

Employee

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Sutro Biopharma
December 7, 2020
www.prnewswire.com:443
/PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...
Sutro Biopharma
December 7, 2020
www.prnewswire.com:443
/PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...
Amirah Al Idrus
December 4, 2020
FierceBiotech
Sutro Biopharma's lead antibody-drug conjugate beat back ovarian cancer in a small phase 1 study, shrinking tumors in 13% of patients who had tried a median of six other treatments including chemotherapy, Genentech's Avastin, PARP inhibitors and checkpoint inhibitors.
Sutro Biopharma
December 3, 2020
www.prnewswire.com:443
/PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...
December 1, 2020
BioSpace
Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors - read this article along with other careers information, tips and advice on BioSpace
BioSpace
November 18, 2020
BioSpace
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, announced today the appointment of two executives to the Company's leadership team.
Sutro Biopharma
November 18, 2020
www.prnewswire.com:443
/PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...
BioSpace
May 21, 2020
BioSpace
Sutro Biopharma, Inc. announced the appointment of Craig Berman, M.D., as Vice President of Clinical Development and the promotion of Regina Cheng to Vice President of Finance and Controller.
BioSpace
May 21, 2020
BioSpace
Sutro Biopharma, Inc., a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, announced the appointments of Carlos Paya, M.D., Ph.D., as Chair of the Scientific Advisory Board and Lainie Martin, M.D., as a member of the Clinical Advisory Board.
National Hispanic Health Foundation
Invalid Date
www.prnewswire.com:443
LOS ÁNGELES, 11 de diciembre de 2018 /PRNewswire-HISPANIC PR WIRE/ -- El jueves 13 de diciembre, la Fundación Nacional para la Salud Hispana (National Hispanic ...
National Hispanic Health Foundation
Invalid Date
www.prnewswire.com:443
LOS ANGELES, Dec. 11, 2018 /PRNewswire/ -- On Thursday, December 13th, the National Hispanic Health Foundation will honor outstanding health professional...
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.